1 minute reading time (68 words)

Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics

Eli Lilly and Company announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain. CNTX-0290, is a novel, small molecule somatostatin receptor type 4 (SSTR4) agonist that is currently being studied in Phase 1 clinical testing as a potential non-opioid treatment for chronic pain conditions. 

Related Posts